Effect of heart rate control on coagulation status in patients of rheumatic mitral stenosis with atrial fibrillation – A pilot study  by Yusuf, Jamal et al.
Original Article
Effect of heart rate control on coagulation status in
patients of rheumatic mitral stenosis with atrial
fibrillation – A pilot study§
Jamal Yusuf a, Mayank Goyal b, Saibal Mukhopadhyay a,*, Vimal Mehta a,
Sunil Dhaiya c, Renu Saxena d, Vijay Trehan a
aProfessor, Department of Cardiology, G.B. Pant Hospital, New Delhi, India
bSenior Resident, Department of Cardiology, G.B. Pant Hospital, New Delhi, India
cSenior Research Fellow, Department of Hematology, AIIMS, New Delhi, India
dProfessor, Department of Hematology, AIIMS, New Delhi, India
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) s 4 0 – s 4 5
a r t i c l e i n f o
Article history:
Received 27 December 2014
Accepted 30 June 2015
Available online 23 November 2015
Keywords:
Atrial ﬁbrillation
Mitral stenosis
Heart rate
Systemic coagulation
Thromboembolism
a b s t r a c t
Background and aim of study: Systemic thromboembolism is a major complication in patients
of mitral stenosis (MS) with atrial ﬁbrillation (AF) due to induction of hypercoagulable state.
The aim was to assess the relationship, if any, between control of ventricular rate and
systemic coagulation factors.
Method: 70 patients of moderate to severe MS in AF were studied. 35 patients with average heart
rate >100 beats/min over a 24 hour period assessed by Holter monitoring were considered as
having a uncontrolled ventricular rate (Group A) and those with average heart rate ≤100 beats/
min as controlled ventricular rate (Group B). 30 healthy volunteers acted as controls.
Results: Plasma concentration of prothrombin fragment 1 + 2 (PF1 + 2) 6600 pmol/ml [inter-
quartile range (IQR) 5400.0–9500], thrombin antithrombin III 22.0 ng/ml [IQR 18.6–28.0], and
plasminogen activator inhibitor 46.8 ng/ml [IQR 44.0–54.0] were elevated in Group A as
compared to Group B (5400 pmol/ml [IQR 3600–7700] p = 0.009, 16.0 ng/ml [IQR 11.0–18.5]
p < 0.001, and 25.8 ng/ml [IQR 20.9–34.4] p < 0.001), respectively. A signiﬁcant correlation was
found between heart rate and all three coagulation markers. Multivariate multiple regres-
sion analysis showed only heart rate to be an independent predictor of systemic coagulation
activation and risk of thrombus formation.
Conclusion: Control of ventricular rate in subjects of MS with AF produces signiﬁcant
reduction in the activation of the coagulation system and may decrease risk of thrombosis.
# 2015 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.
§ Read the Editorial to this manuscript: Hypercoagulable state in mitral stenosis with atrial ﬁbrillation: Can strict rate control prevent
thrombus formation?
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Rheumatic heart disease (RHD) is a major health problem in our
country. Mitral stenosis (MS) is the most common manifesta-
tion, and atrial ﬁbrillation (AF) develops in 40% patients.1
Though MS per se induces a hypercoagulable state,2–5 develop-
ment of AF is an indication for initiating oral anti-coagulant
therapy to prevent systemic thromboembolism. However, risk
of bleeding often prevents treating physicians of our country
from prescribing vitamin K antagonist (VKA) in these patients.
This is due to the fact that VKA therapy warrants regular
assessment of International Normalized Ratio (INR) to monitor
efﬁcacy and safety of drug. However, in our country, RHD often
afﬂicts subjects of poor socioeconomic status, in whom not only
lack of facilities to monitor (INR) but also the cost involved
makes them reluctant to use VKA. Studies have revealed that
rate control strategy is not inferior to rhythm control strategy in
preventing cardiovascular morbidity and mortality including
risk of thromboembolism in patients of nonvalvular AF.6,7
Hypothesizing that rate control per se may have a beneﬁcial
effect on systemic hypercoagulable state, Atak et al.8 in a small
interesting study had shown that control of ventricular rate per
se with AV nodal blocking drugs produced signiﬁcant decrease
in systemic level of procoagulants in patients of MS with AF.
However one the shortcoming of the study was that patients
were considered to have controlled or uncontrolled ventricular
rate on the basis of a single resting ECG showing ventricular rate
≤100/min and >100/min, respectively. As a result, the level of
systemic procoagulants in patients with controlled ventricular
rate was reported as similar to those in healthy controls.
However, rate control per se is unlikely to decrease level of
procoagulants in patients of MS with AF to that in normal
subjects. Hence we decided to conduct a pilot study to restudy
the systemic coagulation factors in patients with controlled
ventricular rate verses uncontrolled ventricular rate (average
heart rate ≤100/min or >100/min) assessed over 24 hour period
by Holter monitoring. We felt that assessment of the procoa-
gulants in patients with controlled ventricular rate over
24 hours would help to overcome the shortcoming of the
previous study.
2. Clinical materials and methods
2.1. Patients
Patients were recruited for the study from the Cardiology
Outpatient Department of our hospital, a tertiary care Centre
between September 2013 and August 2014. Patients with clinical
evidence of signiﬁcant MS in AF not on any VKA therapy (either
never prescribed by treating physician before referral or had
stopped therapy for at least 3 weeks prior to presentation in the
OPD) were considered for the study. A screening 2D Echo and
resting 12 lead ECG was done to conﬁrm the presence of
signiﬁcant MS (moderate to severe; MVA <1.5 cm2) and AF
without associated signiﬁcant mitral regurgitation (MR) (mod-
erate to severe) or aortic valve disease (moderate to severe aortic
stenosis and/or aortic regurgitation). All patients underwent
detailed Trans Thoracic Echocardiography (TTE) in order toevaluate valvular involvement in the study group and to exclude
cardiac disease in control subjects using Philips iE33 ﬁtted with a
commercially available 5 MHz transducer. The mitral valve area
(MVA) was calculated using both planimetry and pressure half-
time methods. Mean transmitral diastolic gradients and
pulmonary artery systolic pressure (PASP) were also measured
by Doppler studies. All echocardiographic examinations were
performed 5–10 times, as patients were in AF9; the mean values
of the replicate measurements were calculated. Patients with
moderate to severe MS (MVA <1.5 cm2) with concomitant mild
and/or absent MR were included in the study. Trans Esophageal
Echocardiography was done in all cases to look for LA/LAA
thrombus and left atrial spontaneous echo contrast (LASEC).
Patients with LA/LAA thrombus and LASEC were excluded from
study, as like LA thrombus,10 presence of LASEC has also been
shown to increase systemic levels of peptide byproducts of
coagulation cascade like PF1 + 2.11 Other exclusion criteria were
coexistent left ventricular (LV) dysfunction (ejection fraction
<45%), pregnancy, prolonged activated partial prothrombin
time (aPTT) or INR, antiplatelet or anticoagulation therapy,
diabetes mellitus, renal and hepatic dysfunction, overt malig-
nancy, chronic inﬂammatory disease, history of systemic and/
or pulmonary embolism, history of deep venous thrombosis,
and NYHA class IV patients.
After preliminary evaluation, eligible patients were sub-
jected to 24 hour Holter monitoring. We deﬁned controlled
ventricular rate as patients having average heart rate ≤100/min
along with no individual rate >110% of maximum predicted
heart rate for the age of the patient over a 24 hour period as
was used in AFFIRM trial.7 Based on the reports of the Holter,
patients were accordingly stratiﬁed as either having controlled
(≤100/min) or uncontrolled ventricular rate (>100/min).
We decided to study 100 subjects [70 cases and 30 controls] in
this preliminary cross sectional pilot study to assess effect of
heart rate on systemic coagulation factors (prothrombin
fragment 1 + 2 (PF1 + 2), thrombin antithrombin III (TAT)) and
plasminogen activator inhibitor (PAI-1) by ELISA. Accordingly,
we recruited 35 patients, each with either controlled or
uncontrolled ventricular rate (as deﬁned in our study) and 30
healthy volunteers as control group for our study. The controls
had no echocardiographic evidence of structural heart disease,
were in sinus rhythm and had all other exclusion criteria
identical to study patients. The study protocol was approved by
the ethical committee of our institution, and informed consent
was obtained from each subject included in the study.
2.2. Hematological investigation
Baseline laboratory tests [(hemogram, erythrocyte segmenta-
tion rate, renal function tests, liver function tests, PT
(prothrombin time), aPTT, ﬁbrinogen and platelet count)] were
done in all subjects of our study (cases and controls).
Peripheral venous samples of the study subjects for measuring
levels of plasma coagulation parameters, including PAI-1, TAT
and PF1 + 2 were drawn in the morning between 8 and 10 AM.
Samples were taken using 21-G vacuum tube phlebotomy
needles into 3.8% 1:9 trisodium citrate-containing tubes,
without venous stasis. The plasma was immediately separat-
ed by centrifugation of blood (3000  g for 15 min), and then
stored in several aliquots at 70 8C until used for assay.
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) s 4 0 – s 4 5S42Plasma PF1 + 2 (enzyme linked immunosorbent assay;
Sincerebio, China; normal human plasma values are 31.2–
2000 pmol/ml; intra- and inter-assay coefﬁcient of variation of
<8% and <10%, respectively) and plasma TAT (enzyme linked
immunosorbent assay; Assaypro, USA; normal human plasma
values are 0.5–10 ng/ml; intra- and inter-assay coefﬁcients of
variation were <5% and <8%) concentrations as markers of
in vivo thrombin generation were measured using solid-phase
sandwich enzyme linked immunosorbent assay method,
respectively. Measurement of PAI-1 employed a quantitative
sandwich enzyme immunoassay (Assaypro, USA; normal
plasma values are 5–40 ng/ml; intra- and inter-assay of
coefﬁcients of variation were <5% and <8%) and was a
reﬂection of endogenous ﬁbrinolytic activity. Analysis of the
plasma samples was done in Department of Hematology,
AIIMS, New Delhi.
2.3. Statistical analysis
The data were analyzed by statistical software SPSS version 16
(IL, Chicago). Normality was tested by skewness and kurtosis
test and also visually by Box–Whisker plot. One-way analysis of
variance was followed by multiple comparison Tukey's test for
normally distributed variables and having homogenous var-
iances across the groups. Welch test and Dunnett T3 test were
applied, when variances were heterogeneous across the groups.
Non-normal variables were compared by performing Kruskal–
Wallis test, and pair-wise comparison was done by Mann–
Whitney test with Bonferroni adjustment. The Spearman
correlation test was done to assess the correlation of coagula-
tion factors with heart rate. To ﬁnd the predictors of systemic
hypercoagulable state in subjects of MS with AF, ﬁve potential
variables considered in the previous study were included.8 The
multivariate multiple regression was applied considering the
three coagulation markers of our study as dependent and the
ﬁve variables (heart rate, mean diastolic gradient, PASP, MVA,
and LA diameter) as independent variables. The univariate and
multivariate results were determined. The normality of
residuals was tested for the regression assumption.
3. Results
The clinical, echocardiographic and hematological variables in
patients with uncontrolled ventricular rate (Group A) andTable 1 – Baseline demographics and levels of coagulation fact
heart rate (Group B) and in controls (Group C).
Variable Mitral stenosis group Cont
(
Group A (n = 35) Group B (n = 35) 
Age (years) 31.86 (5.24) 28.97 (5.48) 31.1
Sex (male), n (%) 16 (45.7%) 13 (37.1%) 14 (
PF1 + 2 (pmol/ml) 6600 [5400.0–9500] 5400 [3600–7700] 1110 [
TAT (ng/ml) 22.0 [18.6–28.0] 16.0 [11.0–18.5] 9.3
PAI-1 (ng/ml) 46.8 [44.0–54.0] 25.8 [20.9–34.4] 12.4
Mean (SD), n (%), median [IQR].
NS, non-signiﬁcant; PAI-1, plasminogen activator inhibitor; TAT, thrombcontrolled ventricular rate (Group B) are presented in Tables 1
and 2. There was no signiﬁcant difference in age or sex ratio
between these groups. However patients with uncontrolled
ventricular rate were more symptomatic with signiﬁcantly
higher percentage of patients in NYHA functional class III [80%
vs 57%, p ≤ 0.05]. There was no signiﬁcant difference in LA
diameter, MVA or PASP between the two groups, but the mean
transmitral gradient was signiﬁcantly higher in Group A
compared to Group B ( p < 0.01) (Table 2). The platelet count,
INR and aPTT were also similar between the two groups, while
serum ﬁbrinogen was signiﬁcantly higher in Group A than
Group B (Table 2). The mean heart rate in Group A was 125.6
 12.5 beats/min compared to 75.68  11.8 beats/min in Group
B patients, and the difference between two groups was
statistically signiﬁcant. Though there was no signiﬁcant
difference in the percentage of patients on beta blockers (b
blockers) or non-dihydropyridine calcium channel blocker
(CCB), higher percentage of patients in Group B were on
digoxin or on combination of digoxin and b blockers or CCB.
Further in Group A, majority of patients were on subtherapeu-
tic doses of AV nodal blocking drugs. The mean plasma
concentration of PF1 + 2, TAT and PAI-1 was signiﬁcantly
higher in Group A patients compared to Group B and control
subject (Table 1). Similarly the plasma concentration of all
three coagulation factors was signiﬁcantly elevated in Group B
as compared to control subjects.
On univariate multiple linear regression analysis, when the
effect of heart rate along with four other variables was
regressed on individual coagulation markers (at alpha of 0.05),
heart rate was found to have signiﬁcant effect on the level of all
three coagulation markers, while MVA and PASP did not have
signiﬁcant effect on level of any of the coagulation markers
(Table 3). Mean diastolic gradient was found to have signiﬁcant
effect on levels of PAI-1 ( p = 0.02) and TAT ( p = 0.02) but not on
PF1 + 2 while LA diameter has signiﬁcant effect on TAT only
(p = 0.017).
On multivariate multiple linear regression, when all the
three coagulation markers were analyzed together, ventricular
rate was found to have signiﬁcant independent effect on the
coagulation markers (p < 0.001). LA diameter ( p = 0.06) and
mean transmitral gradient (p = 0.07) failed to show signiﬁcant
independent effect on the coagulation activity at a = 0.05, but if
type I error is relaxed to 8%, then these two variables were also
independent predictors of increased systemic coagulation.
However MVA and PASP were found to have no signiﬁcantors in patients with uncontrolled (Group A) and controlled
rol group C
n = 30)
Over all
signiﬁcance
Multiple comparison ( p value)
Group A
vs B
Group B
vs C
Group A
vs C
4 (3.35) 0.068 NS NS NS
40.0%) 0.759 NS NS NS
360–1750] <0.001 0.009 <0.001 <0.001
0 (6.4–11.30) <0.001 <0.001 <0.001 <0.001
 (7.5–21.8) <0.001 <0.001 <0.001 <0.001
in antithrombin; PF, prothrombin fragment 1 + 2.
Table 2 – Clinical, hematological, and echocardiographic characteristics of patients with uncontrolled and controlled heart
rate.
Variable Mitral stenosis group p value
Group A (n = 35) Group B (n = 35)
Heart rate (beats/min) 125.6 (12.5) 75.68 (11.8) <0.001
NYHA functional class
NYHA II 7 (20%) 15 (42.9%) NS
NYHA III 28 (80%) 20 (57.1%) <0.01
Palpitation 30 (85%) 28 (80%) NS
Medication for rate control
Digitalis 21 (60%) 31 (89%) <0.001
Beta blocker 28 (80%) 31 (89%) NS
Calcium channel blocker 4 (11%) 7 (20.0%) NS
Digitalis + beta blocker 14 (40%) 26 (74%) NS
Digitalis + calcium channel blocker 4 (11%) 7 (20%) NS
Hematological variables
INR 1.04 (0.10) 1.04 (0.07) NS
APTT 31.8 (5.8) 32.2 (6.0) NS
Platelets (*109/l) 260 (47) 256 (35) NS
Fibrinogen (mg/dl) 483 (141.9) 388.7 (132.4) <0.01
Echo cardio graphic parameters
Mitral valve area (2D, cm2) 0.9 (0.14) 0.87 (0.15) NS
Left atrium diameter (mm) 47.54 (6.59) 45.26 (5.42) NS
Mean trans mitral diastolic gradient (mm Hg) 18.57 (5.60) 14.37 (4.29) <0.01
PASP (mm Hg) 48.59 (12.62) NS
Mean (SD), n (%).
NS, non-signiﬁcant; NYHA, New York Heart Association; INR, International Normalized Ratio, APTT, activated partial thromboplastin time;
PASP, pulmonary artery systolic pressure.
Table 3 – Univariate and multivariate multiple regression analyses of various factors predictive of hypercoagulable state in
subjects of MS with AF.
Coagulation markers p value R2
Heart rate
(beats/min)
MV area
(cm2)
LA diameter
(mm)
Mean diastolic
gradient (mm Hg)
PASP
(mm Hg)
All ﬁve
together
PAI-1 (ng/ml) <0.001 0.139 0.469 0.020 0.967 <0.001 0.7810
TAT (ng/ml) <0.001 0.260 0.017 0.018 0.961 <0.001 0.4774
PF1 + 2 (pmol/ml) <0.001 0.674 0.828 0.124 0.822 <0.001 0.3266
All coagulation markers
together
<0.001 0.474 0.069 0.073 0.996 <0.001
PAI-1, plasminogen activator inhibitor; TAT, thrombin antithrombin; PF, prothrombin fragment 1 + 2.
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) s 4 0 – s 4 5 S43independent effect on coagulation markers in our study
(Table 3).
A signiﬁcant correlation was found between heart rate and
plasma levels of all the coagulation factors assessed by
Spearman correlation test [PAI-1: r = 0.711, p < 0.001; TAT:
r = 0.545, p = 0.001; PF1 + 2: r = 0.645, p < 0.001].
4. Discussion
Our present study has shown that systemic coagulation
activity is signiﬁcantly increased in patients of MS in AF with
fast ventricular rate (average heart rate >100/min) compared
to those with controlled heart rate (average heart rate ≤100/
min). In addition, mean diastolic gradient was signiﬁcantly
higher in patients with fast ventricular rate and could also be a
predictor of systemic coagulation activity. Our study resultsare in agreement with the study by Atak et al.8 To the best of
our knowledge, no other study data are available in world
literature evaluating the effect of heart rate control on
systemic coagulation factors in patients of nonvalvular AF.
Unlike the study by Atak et al.,8 where there was no
statistically signiﬁcant difference in level of procoagulants
in patients with controlled ventricular rate (resting heart rate
79.8  12.1/min) compared to healthy controls, in our study the
level of procoagulants was signiﬁcantly higher in patients with
controlled ventricular rate (mean heart rate 75.86  11.8/min)
compared to healthy controls (in sinus rhythm with resting
heart rate 68.9  9.7/min). So we feel, based on our pilot
study results, adequately powered future studies should be
planned to assess the effect of strict heart rate control (resting
heart rate between 60 and 80 beats/min) compared to moder-
ate rate control (resting heart rate <100/min) in patients with
valvular AF.
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) s 4 0 – s 4 5S44The mechanism proposed to explain prothrombotic state in
MS is obstruction to ﬂow across the mitral valve leading to
increase in the pressure in the LA and blood stasis. This
phenomenon in turn leads to activation of platelets, the
coagulation system and predisposition to thrombus forma-
tion.12 When the heart rate increases, the diastolic ﬁlling time
decreases more than that of systole and thus results in an
increase of the trans mitral gradient, LA pressure and blood
stasis in left atrium. Accordingly, there is higher degree of
activation of the coagulation system with higher rates com-
pared to lower rates in background of similar degree of stenosis
of mitral valve as shown in our study. Similarly AF per se is a risk
factor for thrombus formation and systemic thromboembolism
due to induction of hypercoagulable state.13–16 During thrombin
generation, the amino terminus of the prothrombin molecule is
released as the inactive F 1 + 2 fragment. The generated
thrombin is inhibited by the endogenous heparin sulfate-
antithrombin III mechanism to form thrombin-antithrombin III
(TAT). Thus PF 1 + 2 and TAT have been used as markers of
in vivo thrombin generation, and the presence of LA thrombus
in MS has been reported to be associated with increased
systemic levels of by-products of coagulation cascade like PF1
+ 2, TAT, and D-dimer.10,17 In patients of MS without LA
thrombus studies have also reported about increased peripheral
venous level of PF1 + 2, TAT and ﬁbrinopeptide A implying that
systemic hypercoagulable state precedes and perhaps predis-
poses to thrombus formation.8,18 Our study results are also in
agreement with these studies. It has been suggested that
coagulation activity may be increased locally within the left
atrium compared to the peripheral systemic bed in patients of
MS with conﬂicting reports. While Li-Saw-Hee et al.19 in their
study could not ﬁnd signiﬁcant difference in level of pro
coagulants in LA and peripheral veins of patients with MS and
chronic AF, ATAK et al.10 and Pevrill et al.20 reported increased
level of procoagulants in LA compared to systemic venous
system in patients of MS either in sinus rhythm or in AF.
However, in both of these studies, it was shown that the
presence of LASEC in LA was responsible for the enhanced
activation of local coagulation system, resulting in higher local
level of procoagulants compared to that in the systemic venous
system.10,20 The third factor, PAI-1, we studied is regarded as a
major determinant of ﬁbrinolytic activity and high levels denote
decreased ﬁbrinolytic activity and a prothrombotic state.
In patients with concomitant MS and AF, the risk of stroke
increases 17 fold compared to 5 fold in patients with
nonvalvular AF.21 Hence these patients are candidates of oral
anticoagulant therapy. In patients with AF secondary to mitral
valve disease, only VKA are recommended for treatment, in
spite of their myriad drug–drug and drug–food interaction,
mandating regular assessment of its efﬁcacy and safety by
monitoring INR.22 But in a developing country like ours where
RHD is a major health problem primarily affecting poor section
of the society, prescribing and follow-up of patients on VKA are
a big challenge for treating physicians due to reluctance on
part of patients to periodically monitor INR. Though the newer
anticoagulants evaluated in patients with nonvalvular AF
have been found to be safer and more efﬁcacious than VKA,23
they have not been adequately evaluated in patients with
valvular AF and are presently not recommended in this subset
of patients.24Our study has shown that control of ventricular rate per se
produces signiﬁcant decrease in the hypercoagulable state and
thus decreases the risk of clot formation and thromboembo-
lism. As rate control decreases the hypercoagulable state, we
can infer that it would also decrease the dose of oral
anticoagulants required to achieve therapeutic INR in patients
with controlled ventricular rate compared to uncontrolled
ventricular rate. In this context, we feel that the results of our
study should be encouraging for the treating physicians.
Aggressive control of ventricular rate in patients with MS with
AF will not only decrease the risk of systemic thromboembo-
lism per se but also make therapy with VKA safer by
decreasing the dose requirement.
5. Limitation of study
Due to small sample size, we were also unable to compare the
coagulation factor levels in subjects with average heart rate
≤80/min compared to those with ≤100/min, which should be
assessed in future studies.
6. Conclusion
The control of ventricular rate in subjects of MS with AF
produces signiﬁcant reduction in activation of the coagulation
system and may decrease risk of thromboembolism.
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